Stanowisko ESC dotyczace toksycznego wplywu leczenia onkologicznego na uklad sercowo-naczyniowy w 2016 roku, opracowane pod auspicjami Komisji ESC do spraw Wytycznych Postepowania.
Zamorano, Jose Luis; Lancellotti, Patrizio; Munoz, Daniel Rodriguezet al.
2016 • In Kardiologia Polska, 74 (11), p. 1193-1233
Stanowisko ESC dotyczace toksycznego wplywu leczenia onkologicznego na uklad sercowo-naczyniowy w 2016 roku, opracowane pod auspicjami Komisji ESC do spraw Wytycznych Postepowania.
Alternative titles :
[en] 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 2013; 49: 1374-1403.
Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 2012; 62: 220-241.
Ewer MS, Ewer SM Cardiotoxicity of anticancer treatments. Nat Rev Cardiol, 2015; 12: 620.
Armstrong GT, Oeffinger KC, Chen Y et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol, 2013; 31: 3673-3680.
Suter TM, Ewer MS Cancer drugs and the heart: importance and management. Eur Heart J, 2013; 34: 1102-1111.
Khouri MG, Douglas PS, Mackey JR et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation, 2012; 126: 2749-2763.
Oeffinger KC, Mertens AC, Sklar CA et al.; Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med, 2006; 355: 1572-1582.
Limat S, Daguindau E, Cahn JY et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. J Clin Pharm Ther, 2014; 39: 168-174.
Hall PS, Harshman LC, Srinivas S, Witteles RM The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail, 2013; 1: 72-78.
Swain SM, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 2003; 97: 2869-2879.
Yeh ET, Bickford CL Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 2009; 53: 2231-2247.
Todaro MC, Oreto L, Qamar R et al. Cardioncology: state of the heart. Int J Cardiol, 2013; 168: 680-687.
Herrmann J, Lerman A, Sandhu NP et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc, 2014; 89: 1287-1306.
Truong J, Yan AT, Cramarossa G, Chan KK Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol, 2014; 30: 869-878.
Svoboda M, Poprach A, Dobes S et al. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol, 2012; 12: 191-207.
Bhave M, Akhter N, Rosen ST Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park), 2014; 28: 482-490.
Curigliano G, Mayer EL, Burstein HJ et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis, 2010; 53: 94-104.
Monsuez JJ, Charniot JC, Vignat N, Artigou JY Cardiac side-effects of cancer chemotherapy. Int J Cardiol, 2010; 144: 3-15.
Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev, 2011; 37: 300-311.
Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 2008; 83: 679-686.
Ryberg M, Nielsen D, Cortese G et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst, 2008; 100: 1058-1067.
Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005; 365: 1687-1717.
Hershman DL, McBride RB, Eisenberger A et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol, 2008; 26: 3159-3165.
Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardio-myopathy. N Engl J Med, 2000; 342: 1077-1084.
Bristow MR, Thompson PD, Martin RP et al. Early anthracycline cardiotoxicity. Am J Med, 1978; 65: 823-832.
Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res, 1983; 43: 4543-4551.
Lim CC, Zuppinger C, Guo X et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem, 2004; 279: 8290-8299.
Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med, 2012; 18: 1639-1642.
Shan K, Lincoff AM, Young JB Anthracycline-induced cardioto-xicity. Ann Intern Med, 1996; 125: 47-58.
Franco VI, Lipshultz SE Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young, 2015; 25 (SUPPL. 2): 107-116.
Drafts BC, Twomley KM, D'Agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging, 2013; 6: 877-885.
Sawyer DB, Peng X, Chen B et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis, 2010; 53: 105-113.
Vejpongsa P, Yeh ET Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol, 2014; 64: 938-945.
Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991; 266: 1672-1677.
Von Hoff DD, Layard M W, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979; 91: 710-717.
Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 2015; 131: 1981-1988.
Eschenhagen T, Force T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2011; 13: 1-10.
Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol, 2010; 55: 213-220.
Chow EJ, Chen Y, Kremer LC et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol, 2015; 33: 394-402.
Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol, 1991; 9: 1215-1223.
Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med, 1981; 141: 758-763.
Mackey JR, Martin M, Pienkowski T et al. TRIO/BCIRG 001 Investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol, 2013; 14: 72-80.
Gollerkeri A, Harrold L, Rose M et al. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int J Cancer, 2001; 93: 139-141.
Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev, 2012; 4: CD006243.
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344: 783-792.
Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol, 2015; 33: 1760-1769.
Bowles EJ, Wellman R, Feigelson HS et al., Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst, 2012; 104: 1293-1305.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al., Herceptin Adjuvant Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 2013; 382: 1021-1028.
de Azambuja E, Procter MJ, van Veldhuisen DJ et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol, 2014; 32: 2159-2165.
Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 2012; 30: 3792-3799.
Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol, 2007; 25: 3859-3865.
Cote GM, Sawyer DB, Chabner BA ERBB2 inhibition and heart failure. N Engl J Med, 2012; 367: 2150-2153.
Ewer MS, Lippman SM Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol, 2005; 23: 2900-2902.
de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol, 2009; 4: 77-88.
Yu AF, Yadav NU, Lung BY et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat, 2015; 149: 489-495.
Piccart-Gebhart M, Holmes E, Baselga J et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol, 2016; 34: 1034-1042.
Krop IE, Suter TM, Dang CT et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol, 2015; 33: 1136-1142.
Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol, 2012; 23: 791-800.
Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol, 2013; 14: 933-942.
Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med, 2013; 369: 722-731.
Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol, 2013; 14: 552-562.
Steingart RM, Bakris GL, Chen HX et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signalling pathway inhibitors. Am Heart J, 2012; 163: 156-163.
Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol, 2014; 78: 748-762.
Ghatalia P, Morgan CJ, Je Y et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol, 2015; 94: 228-237.
Ewer MS, Suter TM, Lenihan DJ et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer, 2014; 50: 2162-2170.
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer, 2007; 7: 332-344.
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol, 2015; 33: 4210-4218.
Shelburne N, Adhikari B, Brell J et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst, 2014; 106.
Fuchs CS, Tomasek J, Yong CJ et al., REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet, 2014; 383: 31-39.
Wilke H, Muro K, Van Cutsem E et al., RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oe-sophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014; 15: 1224-1235.
Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014; 384: 665-673.
Verweij J, Casali PG, Kotasek D et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer, 2007; 43: 974-978.
Valent P, Hadzijusufovic E, Schernthaner GH et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015; 125: 901-906.
Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med, 2013; 369: 1779-1781.
Stewart AK, Rajkumar S V, Dimopoulos MA et al., ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med, 2015; 372: 142-152.
Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction - Alzheimer's disease of the heart? N Engl J Med, 2013; 368: 455-464.
Russell SD, Lyon A, Lenihan DJ et al. Serial echocardiographic assessment of patients (pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 Endeavor Trial (NCT01568866). Blood, 2015; 126: abstract 4250.
Lendvai N, Devlin S, Patel M et al. Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy. Blood, 2015; 126: abstract 4257.
Jaworski C, Mariani JA, Wheeler G, Kaye DM Cardiac complications of thoracic irradiation. J Am Coll Cardiol, 2013; 61: 2319-2328.
Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood, 2007; 109: 1878-1886.
Hooning MJ, Botma A, Aleman BM et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst, 2007; 99: 365-375.
Armstrong GT, Joshi VM, Ness KK et al. Comprehensive echo-cardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol, 2015; 65: 2511-2522.
Ezaz G, Long JB, Gross C P, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc, 2014; 3: e000472.
Plana JC, Galderisi M, Barac A et al. Expert consensus for multimo-dality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2014; 15: 1063-1093.
Cardinale D, Sandri MT Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis, 2010; 53: 121-129.
Curigliano G, Cardinale D, Suter T et al., ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 2012; 23 (SUPPL. 7): vii155-vii166.
Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol, 2010; 28: 3910-3916.
Ky B, Putt M, Sawaya H, French B et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol, 2014; 63: 809-816.
Thavendiranathan P, Poulin F, Lim KD et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol, 2014; 63: 2751-2768.
Lipshultz SE, Adams MJ, Colan SD et al. American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Nutrition Physical Activity and Metabolism. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation, 2013; 128: 1927-1995.
Armenian SH, Hudson MM, Mulder RL et al. International Late Effects of Childhood Cancer Guideline Harmonization Group. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol, 2015; 16: e123-e136.
Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocar-diography and cardiac magnetic resonance imaging. J Clin Oncol, 2012; 30: 2876-2884.
Ewer MS. Anthracycline cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention. In: Ewer MS, Yeh ET eds. Cancer and the Heart. Shelton, CT, USA: People's Medical Publishing House; 2013, 11-41.
Lancellotti P, Nkomo VT, Badano LP et al., European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging, 2013; 14: 721-740.
Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol, 2007; 25: 3808-3815.
Lang RM, Badano L P, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015; 28: 1-39.e14.
Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol, 2003; 92: 226-230.
Hull MC, Morris CG, Pepine CJ, Mendenhall NP Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA, 2003; 290: 2831-2837.
Thavendiranathan P Grant AD, Negishi T et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol, 2013; 61: 77-84.
Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging, 2012; 5: 596-603.
Negishi K, Negishi T, Hare JL et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr, 2013; 26: 493-498.
Voigt JU, Pedrizzetti G, Lysyansky P et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging, 2015; 16: 1-11.
Gottdiener JS, Mathisen DJ, Borer JS et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med, 1981; 94: 430-435.
Bellenger NG, Burgess MI, Ray SG et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J, 2000; 21: 1387-1396.
Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol, 2013; 20: 443-464.
Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging, 2013; 6: 1080-1091.
Penugonda N. Cardiac MRI in infiltrative disorders: a concise review. Curr Cardiol Rev, 2010; 6: 134-136.
Gulati A, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA, 2013; 309: 896-908.
Ky B, Carver JR Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin, 2011; 7: 323-331.
Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol, 2000; 36: 517-522.
Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 2004; 109: 2749-2754.
Ledwidge M, Gallagher J, Conlon C et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA, 2013; 310: 66-74.
Thakur A, Witteles RM Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail, 2014; 20: 155-158.
Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol, 2014; 15: 47.
Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer, 2011; 10: 151-156.
Frickhofen N, Beck FJ, Jung B et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol, 2002; 13: 797-801.
Kosmas C, Kallistratos MS, Kopterides P et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol, 2008; 134: 75-82.
Moore RA, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol, 2011; 29: 3466-3473.
Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-4657.
Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 2003; 21: 1513-1523.
Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 2007; 99: 1232-1239.
Choueiri TK, Schutz FA, Je Y et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol, 2010; 28: 2280-2285.
Lestuzzi C, Vaccher E, Talamini R et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol, 2014; 25: 1059-1064.
Arima Y, Oshima S, Noda K et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol, 2009; 54: 512-515.
McGale P, Darby SC, Hall P et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol, 2011; 100: 167-175.
Virmani R, Farb A, Carter AJ, Jones RM Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol, 1998; 3: 163-172.
Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med, 1981; 70: 519-530.
Veinot JP, Edwards WD Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol, 1996; 27: 766-773.
McEniery PT, Dorosti K, Schiavone WA et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol, 1987; 60: 1020-1024.
King V, Constine LS, Clark D et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys, 1996; 36: 881-889.
Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med, 2013; 368: 987-998.
Storey MR, Munden R, Strom EA et al. Coronary artery dosimetry in intact left breast irradiation. Cancer J, 2001; 7: 492-497.
Correa CR, Litt HI, Hwang WT et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for earlystage breast cancer. J Clin Oncol, 2007; 25: 3031-3037.
Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin's disease. Med Dosim, 1991; 16: 237-241.
Orzan F Brusca A, Conte MR et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J, 1993; 69: 496-500.
van Nimwegen FA, Schaapveld M, Cutter DJ et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol, 2016; 34: 235-243.
van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med, 2015; 175: 1007-1017.
Windecker S, Kolh P Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014; 35: 2541-2619.
Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016; 37: 267-315.
Steg PG, James SK, Atar D et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012; 33: 2569-2619.
Brouwer CA, Postma A, Hooimeijer HL et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol, 2013; 31: 3906-3913.
de Haas EC, Oosting S F, Lefrandt et al. The metabolic syndrome in cancer survivors. Lancet Oncol, 2010; 11: 193-203.
Prosnitz RG, Hubbs JL, Evans ES et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer, 2007; 110: 1840-1850.
Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99 m sestamibi scintigraphy. Eur J Nucl Med, 1997; 24: 286-292.
Malanca M, Cimadevilla C, Brochet E et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr, 2010; 23: 108e101-102.
Cutter DJ, Schaapveld M, Darby SC et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst, 2015; 107: djv008.
Groarke JD, Nguyen PL, Nohria A et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for noninvasive imaging for detection of cardiovascular disease. Eur Heart J, 2014; 35: 612-623.
Vahanian A, Alfieri O, Andreotti F et al., Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J, 2012; 33: 2451-2496.
Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf, 2015; 38: 129-152.
Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist, 2013; 18: 900-908.
Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001; 19: 3852-3860.
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf, 2013; 36: 295-316.
Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol, 2007; 25: 3362-3371.
Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol, 2014; 63: 945-953.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 2015; 36: 2793-2867.
Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA, 2003; 289: 2120-2127.
Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res, 2006; 12: 3871-3874.
Larsen TB, Nielsen PB, Skjoth F et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One, 2014; 9: e114445.
Colt JS, Schwartz K, Graubard BI et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology, 2011; 22: 797-804.
Milan A, Puglisi E, Ferrari L et al. Arterial hypertension and cancer. Int J Cancer, 2014; 134: 2269-2277.
Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 2009; 20: 807-815.
Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic reviewand meta-analysis. Lancet Oncol, 2008; 9: 117-123.
Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med, 2008; 358: 1129-1136.
Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens, 2010; 23: 460-468.
Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2013; 34: 2159-2219.
Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol, 2009; 48: 9-17.
Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens, 2013; 27: 601-611.
Qi WX, He AN, Shen Z, Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol, 2013; 76: 348-357.
Qi WX, Shen Z, Lin F et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol, 2013; 75: 919-930.
Wang Z, Xu J, Nie W et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol, 2014; 70: 225-231.
Maitland ML, Bakris GL, Black HR et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst, 2010; 102: 596-604.
McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2012; 33: 1787-1847.
Oliver JJ, Melville V P, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension, 2006; 48: 622-627.
Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol, 2010; 7: 564-575.
Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension, 2009; 54: 652-658.
Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb, 2006; 35: 103-110.
Di Nisio M, Ferrante N, Feragalli B et al. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res, 2011; 127: 382-383.
Ewer MS, Gluck S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer, 2009; 115: 1813-1826.
Lecumberri R, Marques M, Panizo E et al. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thromb Haemost, 2013; 110: 184-190.
Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw, 2011; 9: 789-797.
Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol, 2009; 27: 4839-4847.
O'Connell CL, Liebman HA. Approach to the management of incidental venous thromboembolic events in patients with cancer. J Natl Compr Canc Netw, 2014; 12: 1557-1560.
Akl EA, Kahale L, Barba M et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev, 2014; 7: CD006650.
Hutten BA, Prins MH, Gent M et al. Incidence of recurrent throm-boembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol, 2000; 18: 3078-3083.
Konstantinides SV, Torbicki A, Agnelli G et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2014; 35: 3033-3069, 3069a-3069k.
Prins MH, Lensing AW, Bauersachs R et al., EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J, 2013; 11: 21.
Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost, 2015; 114: 150-157.
Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag, 2014; 10: 423-436.
Farge D, Debourdeau P, Beckers M et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost, 2013; 11: 56-70.
Barginear MF, Gralla RJ, Bradley TP et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Support Care Cancer, 2012; 20: 2865-2872.
Villemur B, Payraud E, Seetha V et al. [Arterial bypass iterative thrombosis and cancer: three cases]. J Mal Vasc, 2014; 39: 14-17.
Plummer C, Henderson RD, O'Sullivan JD, Read SJ Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke, 2011; 42: 2410-2418.
De Bruin ML, Dorresteijn LD, van't Veer MB et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst, 2009; 101: 928-937.
Yuan H, Gaber MW, Boyd K et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys, 2006; 66: 860-866.
Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol, 1974; 25: 94-104.
Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol, 2005; 44: 13-22.
Tendera M, Aboyans V, Bartelink ML et al., European Stroke Organisation. ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 2851-2906.
Fokkema M, den Hartog AG, Bots ML et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke, 2012; 43: 793-801.
Gujral DM, Shah BN, Chahal NS et al. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol), 2014; 26: 94-102.
Limsuwan A, Pakakasama S, Rochanawutanon M, Hongeng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology, 2006; 105: 188-194.
Farha S, Dweik R, Rahaghi F et al. Imatinib in pulmonary arterial hypertension: c-Kit inhibition. Pulm Circ, 2014; 4: 452-455.
Hoeper MM, Barst RJ, Bourge RC et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation, 2013; 127: 1128-1138.
Montani D, Bergot E, Gunther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012; 125: 2128-2137.
Ranchoux B, Gunther S, Quarck R et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol, 2015; 185: 356-371.
Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J, 2016; 37: 67-119.
Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys, 1995; 31: 1205-1211.
Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients. Am J Cardiol, 1983; 51: 1679-1681.
Gagliardi G, Constine LS, Moiseenko V et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys, 2010; 76: S77-85.
Adler Y, Charron P, Imazio M et al., European Society of Cardiology. 2015 ESC Guidelines for the diagnosis and management of pericar-dial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2015; 36: 2921-2964.
Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 2008; 118: 84-95.
Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol, 2015; 65: 584-585.
Diller L, Chow EJ, Gurney JG et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol, 2009; 27: 2339-2355.
Tukenova M, Guibout C, Oberlin O et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol, 2010; 28: 1308-1315.
Gudmundsdottir T, Winther J F, de Fine Licht S et al. ALiCCS study group. Cardiovascular disease in adult life after childhood cancer in Scandinavia: a population-based cohort study of 32,308 one-year survivors. Int J Cancer, 2015; 137: 1176-1186.
Aapro M, Bernard-Marty C, Brain EG et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol, 2011; 22: 257-267.
Serrano C, Cortes J, De Mattos-Arruda L et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol, 2012; 23: 897-902.
Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf, 2008; 31: 459-467.
Gziri MM, Amant F, Debieve F et al. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat Diagn, 2012; 32: 614-619.
Van Calsteren K, Heyns L, De Smet F et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol, 2010; 28: 683-689.
Gziri MM, Debieve F, de Catte L et al. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstet Gynecol Scand, 2012; 91: 1465-1468.
Van Calsteren K, Verbesselt R, Beijnen J et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclopho-sphamide in a baboon model. Gynecol Oncol, 2010; 119: 594-600.
Cardonick E, Dougherty R, Grana G et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J, 2010; 16: 76-82.
Bosch X, Rovira M, Sitges M et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol, 2013; 61: 2355-2362.
Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J, 2016; 37: 1671-1680.
Pituskin E, Haykowsky M, Mackey JR et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumabmediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer, 2011; 11: 318.
Barac A, Murtagh G, Carver JR et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol, 2015; 65: 2739-2746.
Clarke E, Lenihan D. Cardio-oncology: a new discipline in medicine to lead us into truly integrative care. Future Cardiol, 2015; 11: 359-361.
Okwuosa TM, Barac A. Burgeoning cardio-oncology programs: challenges and opportunities for early career cardiologists/faculty directors. J Am Coll Cardiol, 2015; 66: 1193-1197.
Albini A, Pennesi G, Donatelli F et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst, 2010; 102: 14-25.
Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol, 1992; 10: 117-127.
Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol, 1996; 14: 3112-3120.
Swain SM, Whaley FS, Gerber MC et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol, 1997; 15: 1333-1340.
Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med, 2004; 351: 145-153.
Marty M, Espie M, Llombart A et al. Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol, 2006; 17: 614-622.
Huh WW, Jaffe N, Durand JB et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol, 2010; 27: 546-557.
Asselin BL, Devidas M, Chen L et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol, 2016; 34: 854-862.
van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 2011; 6: CD003917.
Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol, 2007; 25: 493-500.
Barry EV, Vrooman LM, Dahlberg SE et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol, 2008; 26: 1106-1111.
Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 2009; 27: 127-145.
European Medicines Agency. Questions and answers on the review of dexrazoxane-containing medicines, powder for solution for infusion, 500 mg. Outcome of a procedure under Article 31 of Directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Dexrazoxane-31/WC500108011.pdf. Date last accessed 12 April 2016.
Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol, 2006; 48: 2258-2262.
Kaya MG, Ozkan M, Gunebakmaz O et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol, 2013; 167: 2306-2310.
Akpek M, Ozdogru I, Sahin O et al. Protective effects of spirono-lactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail, 2015; 17: 81-89.
Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 2005; 104: 2492-2498.
Yancy CW, Jessup M, Bozkurt B et al. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013; 62: e147-e239.
Negishi K, Negishi T, Haluska BA et al. Use of specke strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging, 2014; 15: 324-331.
Harris L, Batist G, Belt R et al. TLC D-99 Study Group. Liposome-en-capsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 2002; 94: 25-36.
van Dalen EC, Michiels EM et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 2010; 5: CD005006.
O'Brien ME, Wigler N, Inbar M et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol, 2004; 15: 440-449.
Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol, 1997; 15: 1318-1332.
Hayes SC, Spence RR, Galvao DA, Newton RU Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport, 2009; 12: 428-434.
Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol, 2014; 32: 3643-3650.
Low CA, Beckjord E, Bovbjerg DH et al. Correlates of positive health behaviors in cancer survivors: results from the 2010 LIVESTRONG survey. J Psychosoc Oncol, 2014; 32: 678-695.
Mishra SI, Scherer RW, Snyder C et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev, 2012; 8: CD008465.
Lyman GH, Bohlke K, Khorana AA et al. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol, 2015; 33: 654-656.
Agnelli G, Gussoni G, Bianchini C et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol, 2009; 10: 943-949.
Frere C, Debourdeau P, Hij A et al. Therapy for cancer-related thromboembolism. Semin Oncol, 2014; 41: 319-338.
Carrier M, Khorana AA, Moretto P et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med, 2014; 127: 82-86 e81.
Akl EA, Ramly EP, Kahale LA et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev, 2014; 10: CD006468.
Legha SS, Benjamin RS, Mackay B E et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med, 1982; 96: 133-139.
Torti FM, Bristow MR, Howes AE et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med, 1983; 99: 745-749.
Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol, 1995; 13: 2688-2699.
Boyle EM, Morschhauser F Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf, 2015; 14: 601-607.
Safra T, Muggia F, Jeffers S et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol, 2000; 11: 1029-1033.
Lotrionte M, Palazzoni G, Natali R et al. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol, 2009; 135: 72-77.
Sparano JA, Makhson AN, Semiglazov VF et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol, 2009; 27: 4522-4529.
Rafiyath SM, Rasul M, Lee B et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol, 2012; 1: 10.
Lotrionte M, Palazzoni G, Abbate A et al. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol, 2013; 167: 1055-1057.
Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclo-phosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 2006; 24: 5381-5387.
Holmes FA, Rowinsky EK Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol, 2001; 28: 8-14.
Salvatorelli E, Menna P, Cascegna S et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther, 2006; 318: 424-433.
Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of cancer therapy. J Clin Oncol, 2005; 23: 7685-7696.
Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol, 2005; 23: 7811-7819.
Slamon D, Eiermann W, Robert N et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 2011; 365: 1273-1283.
Smith I, Procter M, Gelber RD et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007; 369: 29-36.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005; 353: 1659-1672.
Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005; 353: 1673-1684.
Seicean S, Seicean A, Alan N et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail, 2013; 6: 420-426.
Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer, 2009; 100: 684-692.
Scott JM, Khakoo A, Mackey JR et al. Modulation of anthracy-cline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation, 2011; 124: 642-650.
Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013; 34: 2949-3003.
Saif MW, Shah MM, Shah AR Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf, 2009; 8: 191-202.
Oleksowicz L, Bruckner HW Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med, 1988; 85: 750-751.
Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol, 1990; 29: 1001-1003.
Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev, 2013; 39: 974-984.
Hancock SL, Tucker MA, Hoppe RT Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA, 1993; 270: 1949-1955.
Prosnitz RG, Chen YH, Marks LB Cardiac toxicity following thoracic radiation. Semin Oncol, 2005; 32 (2 suppl. 3): S71-S80.
Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys, 2007; 34: 1354-1363.
Bruzzaniti V, Abate A, Pinnaro P et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res, 2013; 32: 88.
Xu Q, Chen Y, Grimm J, Fan J et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys, 2012; 39: 6621-6628.
Bartlett FR, Colgan RM, Donovan EM et al. The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol, 2015; 114: 66-72.
McCabe MS, Bhatia S, Oeffinger KC et al. American Society of Clinical Oncology statement: achieving highquality cancer survivorship care. J Clin Oncol, 2013; 31: 631-640.
Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer, 2013; 119 (SUPPL. 11): 2131-2142.
Hequet O, Le QH, Moullet I et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol, 2004; 22: 1864-1871.
de Azambuja E, Ameye L, Diaz M et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclo-phosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer, 2015; 51: 2517-2524.
Mitani I, Jain D, Joska TM et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol, 2003; 10: 132-139.
Ewer MS, Lenihan DJ Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol, 2008; 26: 1201-1203.
Lenihan DJ, Cardinale DM Late cardiac effects of cancer treatment. J Clin Oncol, 2012; 30: 3657-3664.
Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol, 2003; 42: 743-749.
Koppelmans V, Vernooij MW, Boogerd W, Seynaeve C, Ikram MA, Breteler MM, Schagen SB Prevalence of cerebral small-vessel disease in long-termbreast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol, 2015; 33: 588-593.
Glanzmann C, Huguenin P, Lutolf UM et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol, 1994; 30: 43-54.
Armstrong GT, Joshi VM, Zhu L et al. Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol, 2013; 31: 774-781.
Copeland KA, Hosmane VR, Jurkovitz C et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol, 2013; 36: 217-221.
Machann W, Beer M, Breunig M et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys, 2011; 79: 1117-1123.
Lenihan DJ, Cardinale D, Cipolla CM The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis, 2010; 53: 88-93.
Moslehi J, Cheng S. Cardio-oncology: it takes two to translate. Sci Transl Med, 2013; 5: 187fs120.
Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist, 2009; 14: 1-11.
Lu CY, Srasuebkul P, Drew AK et al. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? Breast, 2013; 22: 482-487.
Seicean S, Seicean A, Plana JC et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol, 2012; 60: 2384-2390.
Yoon GJ, Telli ML, Kao DP et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol, 2010; 56: 1644-1650.
Lancellotti P, Anker SD, Donal E et al., EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry) - EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging, 2015; 16: 466-470.
